Table I.
Association between the expression of CTGF and clinicopathologic parameters of the EOC cases.
| CTGF expression | ||||||
|---|---|---|---|---|---|---|
| Total | Low | High | ||||
| Characteristics | N | N | % | N | % | P-value |
| Total | 104 | 65 | 62.5 | 39 | 37.5 | |
| Age (years) | 0.4617 | |||||
| ≤50 | 38 | 22 | 33.8 | 16 | 41.0 | |
| >50 | 66 | 43 | 66.2 | 23 | 59.0 | |
| FIGO stage | 0.138 | |||||
| I | 44 | 31 | 47.7 | 13 | 33.3 | |
| II | 20 | 14 | 21.5 | 6 | 15.4 | |
| III | 36 | 17 | 26.2 | 19 | 48.7 | |
| IV | 4 | 3 | 4.6 | 1 | 2.6 | |
| Histological type (WHO) | 0.2283 | |||||
| Serous | 34 | 18 | 27.7 | 16 | 41.0 | |
| Clear-cell | 42 | 27 | 41.5 | 15 | 38.5 | |
| Endometroid | 18 | 12 | 18.5 | 6 | 15.4 | |
| Mucinous | 8 | 7 | 10.8 | 1 | 2.6 | |
| Mixed type | 1 | 1 | 1.5 | 0 | 0.0 | |
| Adenocarcinoma | 1 | 0 | 0.0 | 1 | 2.6 | |
| Chemotherapy | 0.3367 | |||||
| None | 3 | 3 | 4.6 | 0 | 0.0 | |
| Platinum-based | 7 | 5 | 7.7 | 2 | 5.1 | |
| Taxane plus platinum | 94 | 57 | 87.7 | 37 | 94.9 | |
| Period of initial treatment | 0.5496 | |||||
| Before 2005 | 33 | 22 | 33.8 | 11 | 28.2 | |
| After 2006 | 71 | 43 | 66.2 | 28 | 71.8 | |
EOC, epithelial ovarian carcinoma; CTGF, connective tissue growth factor; FIGO, International Federation of Gynecology and Obstetrics.